AnGes, Inc. Logo

AnGes, Inc.

Biopharmaceutical firm developing gene-based and nucleotide-based medicines.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号

Description

AnGes, Inc. is a biopharmaceutical company specializing in the research and development of gene-based and nucleotide-based medicines. The company's core focus is its Hepatocyte Growth Factor (HGF) gene therapy product, designed to treat ischemic diseases by regenerating blood vessels. This product was the first gene therapy medicine to receive marketing approval in Japan. AnGes leverages its expertise in plasmid DNA technology across its development pipeline, which also includes an NFkB decoy oligonucleotide and DNA vaccines. The company is dedicated to developing novel treatments for various conditions, including rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-07 07:30
有価証券届出書(参照方式)
Japanese ZIP 244.5 KB
2025-08-13 06:50
確認書
Japanese ZIP 8.9 KB
2025-08-13 04:19
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese ZIP 488.0 KB
2025-03-31 04:52
臨時報告書
Japanese ZIP 25.5 KB
2025-03-31 03:22
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 23.7 KB
2025-03-31 03:18
確認書
Japanese ZIP 8.9 KB
2025-03-31 03:17
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 1.5 MB
2024-09-03 06:05
訂正有価証券届出書(参照方式)
Japanese ZIP 203.2 KB
2024-08-30 09:06
有価証券届出書(参照方式)
Japanese ZIP 381.2 KB
2024-08-14 02:28
確認書
Japanese ZIP 8.9 KB
2024-08-14 02:27
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese ZIP 725.7 KB
2024-05-14 02:27
確認書
Japanese ZIP 8.9 KB
2024-05-14 02:25
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese ZIP 457.7 KB
2024-03-29 01:45
臨時報告書
Japanese ZIP 24.0 KB
2024-03-29 01:43
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese ZIP 23.6 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAREGEN CO.,LTD. Logo
Develops biomimetic peptides and growth factors for aesthetic and medical solutions.
South Korea
214370
Caribou Biosciences, Inc. Logo
Clinical-stage biopharma developing genome-edited allogeneic cell therapies.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
A clinical-stage biotech developing engineered macrophage-based therapeutics for cancer.
United States of America
CARM
Carna Biosciences, Inc. Logo
Clinical-stage biopharma developing small molecule kinase inhibitors.
Japan
4572
Cartesian Therapeutics, Inc. Logo
A clinical-stage company developing mRNA-engineered cell therapies for autoimmune diseases.
United States of America
RNAC
CASI Pharmaceuticals, Inc. Logo
Biopharmaceutical firm developing therapeutics for organ transplant and autoimmune diseases.
United States of America
CASI
CATALYST PHARMACEUTICALS, INC. Logo
Biopharmaceutical company commercializing drugs for rare neurological and autoimmune diseases.
United States of America
CPRX
cbdMD, Inc. Logo
Producer and distributor of health and wellness CBD products from U.S.-grown hemp.
United States of America
YCBD
CDT Equity Inc. Logo
A clinical-stage biopharmaceutical firm advancing assets for unmet medical needs.
United States of America
CDT
CELADON PHARMACEUTICALS PLC Logo
Researches, cultivates, and manufactures cannabinoid-based medicines for chronic pain.
United Kingdom
CEL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.